Miniatura

Fitxers

901538.pdf (3.83 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-10-01

Llicència de publicació

cc-by-nc-nd (c) Ordi Calvo, Oriol et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/228958

Whole-exome sequencing of vulvar squamous cell carcinomas reveals an impaired prognosis in patients with TP53 mutations and concurrent CCND1 gains

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.modpat.2024.100574

Resum

Very little information is available on the mutational landscape of vulvar squamous cell carcinoma (VSCC), a disease that mainly affects older women. Studies focusing on the mutational patterns of the currently recognized etiopathogenic types of this tumor (human papillomavirus [HPV]-associated [HPV-A], HPV-independent [HPV-I] with TP53 mutation [HPV-I/TP53mut], and HPV-I with wild-type TP53 [HPV-I/TP53wt]) are particularly rare, and there is almost no information on the prognostic implications of these abnormalities.Whole-exome DNA sequencing of 60 VSCC and matched normal tissues from each patient was performed. HPV detection, immunohistochemistry (IHC) for p16, p53, and mismatch repair proteins were also performed. Ten tumors (16.7%) were classified as HPV-A, 37 (61.7%) as HPV-I/TP53mut, and 13 (21.6%) as HPV-I/TP53wt. TP53 was the most frequently mutated gene (66.7%), followed by FAT1 (28.3%), CDKN2A (25.0%), RNF213 (23.3%), NFE2L2 (20%) and PIK3CA (20%). All the 60 tumors (100%) were DNA mismatch repair proficient. Seventeen tumors (28.3%) showed CCND1 gain. Bivariate analysis, adjusted for International Federation of Gynecology and Obstetrics stage, revealed that TP53 mutation, CCND1 gain, and the combination of the 2 alterations were strongly associated with impaired recurrence-free survival (hazard ratio, 4.4; P < .001) and disease-specific survival (hazard ratio, 6.1; P = .002). Similar results were obtained when p53 IHC status was used instead of TP53 status and when considering only HPV-I VSCC. However, in the latter category, p53 IHC maintained its prognostic impact only in combination with CCND1 gains. All tumors carried at least one potentially actionable genomic alteration. In conclusion, VSCCs with CCND1 gain represent a prognostically adverse category among HPV-I/TP53mut tumors. All patients with VSCCs are potential candidates for targeted therapy.

Matèries

Càncer, Genòmica, Malalties de la vulva

Matèries (anglès)

Cancer, Genomics, Vulva diseases

Citació

Col·leccions

Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (ISGlobal)

Citació

ORDI, Oriol, SACO, Adela, PEÑUELAS, Núria, BLANCO IRAZUEGUI, Odei, PINO SALADRIGUES, Marta del, CARRERAS DIEGUEZ, Núria, MARIMON, Lorena, RODRIGO CALVO, María teresa, MORATÓ, Alba, SISUASHVILI, Lia, BUSTAMANTE PINEDA, Mariona, CRUELLS, Adrià, DARECKA, Katarzyna, VEGA, Naiara, ALOS, Silvia, TRIAS PUIGSUREDA, Isabel, FUSTÉ, Pere, PARRA, Genís, GUT, Marta, MUNMANY, Meritxell, TORNÉ BLADÉ, Aureli, JARES GERBOLES, Pedro, RAKISLOVA, Natalia. Whole-exome sequencing of vulvar squamous cell carcinomas reveals an impaired prognosis in patients with TP53 mutations and concurrent CCND1 gains. _Modern Pathology_. 2024. Vol. 37, núm. 10. [consulta: 27 de abril de 2026]. ISSN: 0893-3952. [Disponible a: https://hdl.handle.net/2445/228958]

Exportar metadades

JSON - METS

Compartir registre